Introduction {#s001}
============

D[ermal substitutes for treating]{.smallcaps} burns or chronic wounds, which have risen worldwide due to an increment in life expectancy and developments in intensive care, are some of the first examples of tissue engineering. They are made of natural biological materials (Alloderm^®^, Lifecell Corp., Branchburg, NJ), natural (Integra^®^, Integra LifeSciences, Plainsboro, NJ; Matriderm^®^, Skin & Health Care AG, Billerbeck, Germany) or artificial (Polyactive^®^, Octoplus NV, Leider, The Netherlands) polymers and some of them include cells (Dermagraft^®^, Smith & Nephew, Hull, United Kingdom). They protect the wound from infection and fluid loss and allow the attachment and ingrowth of cells that will form new dermis rather than scar tissue. However, limitations of current products include unreliable integration, poor mechanical properties, size limitations, or high costs. Thus, the clinical need for dermal substitutes continues to be high.^[@B5; @B6; @B7]^

Developing new dermal scaffolds requires *in vitro* testing before *in vivo* experimentation in animal models and ultimately clinical trials. There are many examples in the literature of *in vitro* testing of new scaffolds for dermal reconstruction, which focus on mechanical characterization of the biomaterial, cytotoxicity, and investigation of certain cell--matrix interactions relevant to wound healing.^[@B8; @B9; @B10; @B11; @B12; @B13; @B14]^ However, there are no studies attempting to standardize *in vitro* testing of new dermal scaffolds, which could predict *in vivo* outcomes such as integration, cellularization, and contraction.

Several critical cellular factors may be proposed that contribute to the overall *in vivo* healing trajectory, such as cell viability and proliferation, apoptosis, matrix contraction, alpha-smooth muscle actin (α-SMA), and growth factors expression. These parameters may also allow responses to different scaffolds to be identified. The objectives of this study were (1) to develop a multiparameter *in vitro* model of three-dimensional (3D) cell ingress into dermal scaffolds that studies the main events of wound healing and (2) to evaluate the results in a combinatory manner with a scoring matrix to predict *in vivo* outcome, thus establishing the necessity for further *in vivo* testing of the new dermal scaffold under development. The overall aim of the study was to establish this method as the international golden standard scoring matrix for *in vitro* evaluation of new dermal scaffolds.

Materials and Methods {#s002}
=====================

Cell culture {#s003}
------------

Primary human dermal fibroblasts (HDFs) from three donors were established from routine surgical excisions of normal skin, obtained with informed consent and local ethics committee approval. Pieces of dissected skin (1 mm×1 mm) were cultured dermal side down in T25 tissue culture flasks (eight per flask), in 3 mL of Dulbecco\'s modified Eagle\'s medium (DMEM, 31885-023, Gibco, Paisley, United Kingdom) supplemented with 10% fetal calf serum (10270-106, Gibco), 100 U/mL penicillin and streptomycin (15140-122, Gibco), and 100 μM L-glutamine (25030-024, Gibco) at 37°C with 5% CO~2.~ Medium was changed twice per week. Adherent HDF egress cultures typically establish within 3 weeks. Cells were used at passage 4.

Control monolayer cultures {#s004}
--------------------------

HDFs (5×10^5^) in 50 μL were seeded on 13-mm-diameter borosilicate glass coverslips (631-0150, VWR International, Leighton Buzzard, United Kingdom) in 12-well plates. After 30-min incubation at 37°C with 5% CO~2~, 2 mL of supplemented DMEM was added per well and plates cultured at 37°C with 5% CO~2~. Medium was changed every 3 days.

3D-contractile collagen gels {#s005}
----------------------------

Collagen type I from rat tail tendons, 2.1 mg/mL in 0.6% acetic acid (60-30-810, First Link Ltd, Wolverhampton, United Kingdom), was supplemented with 10X 199 medium (M0650, Sigma-Aldrich, Gillingham, United Kingdom), and approximately 2% (v/v) of 7.5% NaHCO~3~, buffered with 1.4% (v/v) 1 M HEPES pH 7.4; pH was neutralized by adding 1 M NaOH dropwise, assessed by color change from yellow to scarlet. Reagents were kept in an ice bath during preparation as well as the final collagen mixture until mixed with the cells.^[@B15],[@B16]^ Cells (5×10^5^) were mixed with 0.5 mL of collagen mixture, plated into 24-well plates and allowed to polymerize within 60 min at 37°C with 5% CO~2~. Two milliliters of supplemented DMEM were added per well. Gels were gently freed from the plastic surface and allowed to float in the culture medium. Medium was changed every 3 days.

Dermal scaffolds {#s006}
----------------

The following dermal scaffolds were used: (1) Integra, 2.1-mm-thick bilayer of bovine tendon collagen type I/chondroitin-6-sulfate crosslinked with glutaraldehyde and a silicon backing; (2) Matriderm, 1-mm-thick lyophilized layer of bovine collagen types I, III, and V/elastin; and (3) Smart Matrix, 2-mm-thick freeze-dried sheet of bovine fibrin/alginate crosslinked with glutaraldehyde, manufactured in our laboratory.

Dermal scaffolds were cut into 6-mm-diameter discs and tightly fitted in a 96-well plate. Cells (5×10^5^) in 50 μL were seeded per scaffold. Two hundred microliters of supplemented DMEM were added per well, and plates were cultured overnight at 37°C with 5% CO~2~. Scaffolds were transferred to 24-well plates and supplemented with 2 mL of culture medium. Medium was changed every 3 days.

Cell viability and proliferation by alamarBlue activity assay {#s007}
-------------------------------------------------------------

One milliliter of 10% alamarBlue (DAL1025, Invitrogen™, Paisley, United Kingdom) stock diluted into phenol-free supplemented DMEM (11880, Gibco) was added per well and incubated at 37°C with 5% CO~2~ for 3 h. For each sample, 1 mL was transferred to a cuvette (FB55147, Fisher Scientific, Loughborough, United Kingdom), and following the manufacturer\'s instructions, absorbance was measured at 570 nm against air using a M550 double beam UV/visible spectrophotometer (Spectronic Camspec Ltd., Garforth, United Kingdom). Absorbance at 600 nm of phenol-free DMEM was subtracted from sample values.

Annexin V apoptosis assay {#s008}
-------------------------

TACS Annexin V-Biotin kit (4835-01-K, Trevigen, Abingdon, United Kingdom) was used. Annexin V-Biotin working reagent was 1 μL of Annexin V-Biotin, 10 μL of 10×binding buffer and 89 μL of distilled water, diluted 1/100 in phosphate-buffered saline (PBS) and stored in the dark on ice. Samples were washed with cold PBS, incubated in 100 μL Annexin V-Biotin working reagent for 15 min in the dark at room temperature, washed with 1×binding buffer, incubated with 100 μL of streptavidin--fluorescein isothiocyanate (F0422, Dako, Glostrup, Denmark; 1:200 in 1×binding buffer) in the dark at room temperature for 15 min, washed twice with 1×binding buffer and fixed in 4% paraformaldehyde overnight. Samples were washed twice with PBS, permeabilized with two drops of 0.5% Triton X-100/PBS for 5 min at room temperature, washed three times with PBS, and incubated in block buffer (0.5% bovine serum albumin \[BSA\]/PBS, pH 7.4) for 30 min at room temperature. Block buffer was drained into tissue paper and samples were incubated in Alexa Fluor 546-phalloidin (A22283, Invitrogen, Carlsbad, CA; 1:100 in block buffer), for 1 h at room temperature inside a dark humidified chamber, washed five times in wash buffer (0.1% Triton X-100/0.1% BSA/PBS, pH 7.4), then once in PBS and once in distilled water. Samples were transferred to slides with one drop of Vecta Mount™ (H-5000, Vector, Peterborough, United Kingdom) and viewed under a confocal laser microscope (Leica DMIRE2, Leica Microsystems GmbH, Wetzlar, Germany).

Ki67 and α-SMA expression {#s009}
-------------------------

At days 2 and 7 of culture, specimens were fixed in 4% paraformaldehyde overnight and processed as already described in a previous section with Ki67 (Mouse Anti-Rat Ki-67 Antigen, M7248, Dako; 1:100 in block buffer) or α-SMA (Mouse Monoclonal Anti-Actin α-Smooth Muscle, A2547, Sigma-Aldrich; 1:1000 in block buffer) as primary antibodies. Secondary antibody (Alexa Fluor 546, goat anti-mouse, A11003, Invitrogen, USA; 1:100 in block buffer) was used with green phalloidin for Ki67 immunostained samples (Alexa Fluor 488 phalloidin, A12379, Invitrogen, USA; 1:100 in block buffer). Samples were examined by confocal microscopy.

Scanning electron microscopy {#s010}
----------------------------

Fixed specimens (2.5% glutaraldehyde, Agar Scientific, Stansted, United Kingdom) were washed with 0.1 M sodium cacodylate buffer (Agar Scientific) and postfixed in 1% osmium tetroxide (Sigma-Aldrich) in cacodylate buffer for 1 h; then washed in cacodylate buffer, dehydrated through a graded series of industrial methylated spirit (20%--60%) and ethanol (70%--100%), equilibrated in 100% ethanol and left to dry overnight. Specimens were mounted on stubs, gold sputtered coated (Agar Auto Sputter Coater, Agar Scientific) and observed (FEI Inspect F, Oxford Instruments, Oxford, United Kingdom).

Histology {#s011}
---------

Fixed specimens (4% paraformaldehyde) were embedded in paraffin. Four-micrometer sections were taken for hematoxylin and eosin staining and viewed under light microscopy (Zeiss Axiophot, Zeiss, Jena, Germany) with a DC200 Leica digital camera and IC50 software.

Cytokine/growth factor expression profile {#s012}
-----------------------------------------

On days 2 and 7 of culture expression of tumor necrosis factor alpha (TNFα), insulin-like growth factor 1 (IGF1), vascular endothelial growth factor (VEGF), interleukin (IL)-6, fibroblast growth factor b (bFGF), transforming growth factor beta (TGFβ), epidermal growth factor (EGF), and leptin was profiled (EA-1011, Signosis Inc., Sunnyvale, CA). Supernatants (100 μL/well) were pipetted into coated wells and incubated for 1 h at room temperature with gentle shaking, after which wells were washed three times with 200 μL of wash buffer. Diluted biotin-labeled antibody mixture (100 μL/well) was added and incubated as before. After repeating the washing step, diluted streptavidin--horseradish peroxidase conjugate (100 μL/well) was added and incubated for 45 min at room temperature with gentle shaking. After washing, substrate (100 μL/well) was added, followed after 30-min incubation by stop solution (50 μL/well). Absorbance at 450 nm was measured using a microplate reader (Biorad 550, Biorad, Hemel Hempstead, United Kingdom).

Statistical analysis {#s013}
--------------------

Comparisons between groups were made using one-way analysis of variance (SigmaStat 3.5 software). A *p*-value≤0.05 was considered a significant result.

Scoring matrix {#s014}
--------------

Combinatorial evaluation of results was done with a scoring matrix: (1) the new dermal scaffold under evaluation, Smart Matrix, was compared to contractile collagen gels (CCGs), established model of scar formation,^[@B9]^ and to the clinically well-established Integra and Matriderm;^[@B17; @B18; @B19; @B20; @B21]^ (2) no difference between Smart Matrix and the scaffold of reference was marked with 0, a positive difference with 1, and a negative difference with −1. A total positive score suggests an improvement over existing products and therefore the new scaffold should be further evaluated *in vivo*. A negative score or 0 suggests no improvement, and therefore no further *in vivo* evaluation is recommended.

Results {#s015}
=======

SEM of dermal scaffolds {#s016}
-----------------------

The three dermal scaffolds used present microporosity ([Fig. 1](#f1){ref-type="fig"}). In addition, Matriderm and Smart Matrix have nanofibers, densely packed in Smart Matrix, as well as nanopores.

![**(a)** Scanning electron microscopy (SEM) photos of dermal scaffolds. **(b)** Matrix contraction of contractile collagen gels (CCG), Integra (I), Matriderm (MD), and Smart Matrix (SM). **(c)** Cell viability and proliferation by alamarBlue assay of monolayer control (C), contractile collagen gels (CCG), Integra (I), Matriderm (MD) and Smart Matrix (SM) at days 2 and 7 of culture (\*C at day 2 significantly higher, *p*\<0.05, than CCG, I, and MD; ^\#^C at day 7 significantly higher, *p*\<0.05, than CCG and MD; ^+^SM at day 2 significantly higher, *p*\<0.05, than MD; significant increase in alamarBlue activity, *p*\<0.05, between days 2 and 7 for C, CCG, MD, and SM).](fig-1){#f1}

Matrix contraction {#s017}
------------------

The three dermal scaffolds did not contract, while CCGs contracted down to 20% of the initial area ([Fig. 1](#f1){ref-type="fig"}).

Cell proliferation and viability {#s018}
--------------------------------

alamarBlue activity, a colorimetric redox assay of metabolic activity and thus of cell viability and proliferation,^[@B22]^ significantly (*p*\<0.05) increased between days 2 and 7 for all samples and controls except for Integra ([Fig. 1](#f1){ref-type="fig"}). Monolayer cultures showed statistically significant higher activities compared to CCGs (*p*=0.002), Integra (*p*=0.001) and Matriderm (*p*\<0.001) at day 2, and CCGs (*p*=0.009) and Matriderm (*p*=0.047) at day 7. Moreover, at day 2, Smart Matrix was significantly higher than Matriderm (*p*=0.021). Ki67 immunostaining, a cell proliferation marker, confirmed proliferation was maintained throughout the culture period.

Cell morphology {#s019}
---------------

HDF monolayers under SEM showed a typical flattened, elongated morphology with multiple cytoplasmic processes of attachment to the surface and intercellular interactions ([Fig. 2](#f2){ref-type="fig"}). In CCGs after 2 days of culture no surface cells were found, but after 7 days, cells with an irregular stellate shape were observed. The surfaces of dermal scaffolds at both time points were covered by a continuous layer of interconnected cells.

![**(a)** SEM photos of monolayer control (day 2), contractile collagen gel (day 7), Integra (day 2), Matriderm (day 2), and Smart Matrix (day 2) cultured with normal human dermal fibroblasts. **(b)** Hematoxylin and eosin (H&E) staining of 4-μm cross-sections of the different matrixes cultured with normal human dermal fibroblasts for 2 and 7 days. Black arrows point at cells with elongated morphology.](fig-2){#f2}

In histological cross-sections ([Fig. 3](#f3){ref-type="fig"}), CCGs on day 2 showed either a rounded or stellate shape with long cytoplasmic processes, with markedly fewer ones by day 7. On dermal scaffold, elongated cells were observed, which clearly predominated on Smart Matrix compared to Matriderm and Integra.

![Annexin V apoptosis assay. White arrows point at positively stained cells, which present an enhanced green fluorescence over background cells, stained in a green-yellow color. Scale bars=50 μm.](fig-3){#f3}

Annexin V apoptosis assay {#s020}
-------------------------

Binding of annexin V protein to phosphatidylserine (PS) identifies PS flipping from the inner to the outlet layer of the cytoplasmic membrane, an early event in apoptosis.^[@B23]^ Basal levels of apoptosis in proportion to cell density were seen in monolayer controls ([Fig. 3](#f3){ref-type="fig"}).^[@B24]^ Apoptosis markedly increased over the culture period for HDF cultured in CCGs,^[@B25]^ and cells with disrupted morphology were clearly observed at day 7.

Apoptosis in Integra and Smart Matrix was partially masked by scaffold autofluorescence, although the apoptosis levels appeared to correlate with cell density. However, in Matriderm, apoptotic cells were clear, the level appearing higher at day 2 than day 7. These results corroborate the decreased activity observed in the alamarBlue assay for Matriderm at day 2.

α-SMA expression {#s021}
----------------

α-SMA expression ([Fig. 4](#f4){ref-type="fig"}) in monolayer controls was uniform across the sample, with some cells with dense α-SMA filaments.^[@B26]^ In CCGs, α-SMA expression was greater towards the gel edge. Interestingly, in Integra at day 2, α-SMA showed a speckled pattern but at day 7, bundles of α-SMA filaments were apparent. In Matriderm, α-SMA expression was intense and diffuse at day 2, and markedly decreased at day 7, with discrete filaments visible, associated with more elongated morphology. In Smart Matrix α-SMA expression was relatively less intense and uniform at day 2, with positively stained filaments at day 7, concomitant with the elongated morphology.

![Alpha-smooth muscle actin (α-SMA) expression by immunostaining. White arrows point at positively stained cells, which present a bright red fluorescence. Scale bars=50 μm.](fig-4){#f4}

Cytokine/growth factors expression profile {#s022}
------------------------------------------

Expression of some factors ([Fig. 5](#f5){ref-type="fig"}) was reduced in all matrices between day 2 and day 7 (bFGF, IL-6), whereas others increased (VEGF, leptin, TNFα); for others, the effect varied with the matrix (EGF, TGFβ). Expression of IFG1 was very similar to that of the monolayer control, and leptin levels in all 3D matrixes were similarly lower than the monolayer controls. Of each scaffold, CCG gave highest bFGF, TGFβ, and IL-6 expression; Integra gave highest TNFα and high IL-6 expression; Matriderm gave the lowest VEGF and bFGF expression and Smart Matrix gave highest VEGF, high bFGF, and lowest TGFβ, EGF, and TNFα. Only expression of TNFα at day 2 in Smart Matrix was significantly lower than in Integra (*p*=0.027).

![Growth factor and cytokine expression profile of contractile collagen gels (CCG), Integra (I), Matriderm (MD), and Smart Matrix (SM) at days 2 and 7 of culture as percentage of monolayer control (\**p*=0.027). TNFα, tumor necrosis factor alpha; IGF1, insulin-like growth factor 1; VEGF, vascular endothelial growth factor; IL, interleukin; bFGF, fibroblast growth factor b; TGFβ, transforming growth factor beta; EGF, epidermal growth factor.](fig-5){#f5}

Scoring matrix {#s023}
--------------

The scoring matrix ([Table 1](#T1){ref-type="table"}) showed that the new Smart Matrix had a positive total score over the three reference scaffolds.

###### 

[Scoring Matrix]{.smallcaps}

  *Parameter*                                       *Time point*   *Smart Matrix vs. CCG*   *Smart Matrix vs. Integra*   *Smart Matrix vs. Matriderm*
  ------------------------------------------------- -------------- ------------------------ ---------------------------- ------------------------------
  Matrix contraction                                2              1                        0                            0
                                                    7              1                        0                            0
  Cell viability+proliferation (alamarBlue assay)   2              0                        0                            1
                                                    7              0                        0                            0
  Cell viability+proliferation (Ki67 expression)    2              0                        0                            0
                                                    7              0                        0                            0
  Apoptosis (annexin V staining)                    2              1                        0                            1
                                                    7              1                        0                            0
  Morphology (SEM)                                  2              1                        0                            0
                                                    7              1                        0                            0
  Morphology (H&E)                                  2              1                        1                            1
                                                    7              1                        1                            1
  α-SMA expression                                  2              1                        0                            1
                                                    7              0                        0                            0
  Cytokine and growth factor expression profile                                                                          
   VEGF                                             2              0                        0                            0
                                                    7              0                        0                            0
   bFGF                                             2              0                        0                            0
                                                    7              0                        0                            0
   TGFβ                                             2              0                        0                            0
                                                    7              0                        0                            0
   TNFα                                             2              0                        1                            0
                                                    7              0                        0                            0
   IL-6                                             2              0                        0                            0
                                                    7              0                        0                            0
   IGF1                                             2              0                        0                            0
                                                    7              0                        0                            0
   Leptin                                           2              0                        0                            0
                                                    7              0                        0                            0
   EGF                                              2              0                        0                            0
                                                    7              0                        0                            0
  Total                                             9              3                        5                            

CCG, contractile collagen gel; SEM, scanning electron microscopy; H&E, hematoxylin and eosin; α-SMA, alpha-smooth muscle actin; VEGF, vascular endothelial growth factor; bFGF, fibroblast growth factor b; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor alpha; IL, interleukin; IGF1, insulin-like growth factor 1; EGF, epidermal growth factor.

Discussion {#s024}
==========

Classical *in vitro* testing of new dermal scaffolds includes cytotoxicity, mechanical characterization to exclude handling issues or poor mechanical stability, and investigation of certain cell--matrix interactions occurring during wound healing. However, an international standard *in vitro* model that studied the main events of wound healing and evaluated them in a combinatory manner by using a scoring matrix would predict *in vivo* outcomes such as integration, cellularization, and contraction of new dermal scaffolds and therefore would establish the necessity for further *in vivo* testing. The histological outcome of scaffold integration is shown by the organization and morphology of fibroblasts, the major cell type in the dermis.^[@B10]^ Their 3D ingress into dermal scaffolds *in vitro* was the basis for the described model.

The higher cell proliferation seen in Smart Matrix compared to Integra and Matriderm may be due to increased cell attachment, spreading, and infiltration,^[@B27]^ suggesting that when implanted *in vivo* the influx of cells into Smart Matrix would be higher. A correlation between fibroblastoid morphology and phenotype has been long established. Fibroblasts present an elongated, spindle shape, while myofibroblasts, the contractile phenotype responsible for wound closure and scar contraction, show a flattened, irregular shape; the latter phenotype is associated with elevated α-SMA expression.^[@B26],[@B28]^ This study demonstrates this correlation and suggests that cells keep the fibroblastic morphology when cultured on dermal scaffolds compared with CCGs. Moreover, Smart Matrix maintained the fibroblastic phenotype more efficiently than Integra or Matriderm, which could be predictive of reduced wound contraction and less scarring *in vivo*.

We found that the nature of the scaffold gives relatively subtle differences in the expression levels of several important factors, which may contribute to distinct outcomes. Only TNFα expression was significantly lower in Smart Matrix at day 2 compared to Integra. The pro-inflammatory cytokine TNFα may impair fibroblast ingress and promote myofibroblast differentiation through increasing the inflammatory component of the granulation response.^[@B29],[@B30]^ The significantly lower TNFα in Smart Matrix than in Integra at day 2 suggests a cellular response more supportive of fibroblast ingress in Smart Matrix.

The combinatorial evaluation of the results in the scoring matrix showed that Smart Matrix could offer an advantage over existing products and therefore should be further evaluated *in vivo*. Indeed, Smart Matrix has been shown to support rapid capillary formation and cellular ingress *in vivo*,^[@B31],[@B32]^ thus validating the proposed method, which would be useful as an international golden scoring matrix to develop new dermal scaffolds that effectively improve the existing products for better treatment of burns and chronic wounds.
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